Cardiac Magnetic Resonance Imaging of the Myocardium in Chronic Kidney Disease

Eva Kis, Laszlo Ablonczy, G. Reusz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Early stages of chronic kidney disease (CKD) are often underdiagnosed, while their deleterious effects on the cardiovascular (CV) system are already at work. Thus, the assessment of early CV damage is of crucial importance in preventing major CV events. Myocardial fibrosis is one of the major consequences of progressive CKD, as it may lead to reentry arrhythmias and long-term myocardial dysfunction predisposing to sudden death and/or congestive heart failure. Subclinical myocardial fibrosis, with a potential key role in the development of uraemic cardiac disease, can be measured and characterised by appropriate cardiac magnetic resonance (CMR) techniques. Fibrosis detection was initially based on the contrast agent gadolinium, due to the superiority in sensitivity and accuracy of contrast-based methods in fibrosis assessment relative to native techniques. However, the severe consequences of gadolinium administration in uraemia (nephrogenic systemic fibrosis) have forced practitioners to re-evaluate the methodology. In the present overview, we review the possible contrast-based and contrast agent-free CMR techniques, including native T1 relaxation time, extracellular volume and global longitudinal strain measurement. The review also summarises their potential clinical relevance in CKD patients based on recently published studies.

Original languageEnglish
Pages (from-to)134-142
Number of pages9
JournalKidney and Blood Pressure Research
Volume43
Issue number1
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Chronic Renal Insufficiency
Myocardium
Fibrosis
Magnetic Resonance Imaging
Gadolinium
Contrast Media
Magnetic Resonance Spectroscopy
Nephrogenic Fibrosing Dermopathy
Contrast Sensitivity
Uremia
Cardiovascular System
Sudden Death
Cardiac Arrhythmias
Heart Diseases
Heart Failure

Keywords

  • Cardiac magnetic resonance imaging
  • Cardiovascular disease
  • Chronic kidney disease
  • Myocardial fibrosis

ASJC Scopus subject areas

  • Nephrology
  • Cardiology and Cardiovascular Medicine

Cite this

Cardiac Magnetic Resonance Imaging of the Myocardium in Chronic Kidney Disease. / Kis, Eva; Ablonczy, Laszlo; Reusz, G.

In: Kidney and Blood Pressure Research, Vol. 43, No. 1, 01.03.2018, p. 134-142.

Research output: Contribution to journalArticle

@article{9b0a7764e3d04d52b36b036e4bb9bc48,
title = "Cardiac Magnetic Resonance Imaging of the Myocardium in Chronic Kidney Disease",
abstract = "Early stages of chronic kidney disease (CKD) are often underdiagnosed, while their deleterious effects on the cardiovascular (CV) system are already at work. Thus, the assessment of early CV damage is of crucial importance in preventing major CV events. Myocardial fibrosis is one of the major consequences of progressive CKD, as it may lead to reentry arrhythmias and long-term myocardial dysfunction predisposing to sudden death and/or congestive heart failure. Subclinical myocardial fibrosis, with a potential key role in the development of uraemic cardiac disease, can be measured and characterised by appropriate cardiac magnetic resonance (CMR) techniques. Fibrosis detection was initially based on the contrast agent gadolinium, due to the superiority in sensitivity and accuracy of contrast-based methods in fibrosis assessment relative to native techniques. However, the severe consequences of gadolinium administration in uraemia (nephrogenic systemic fibrosis) have forced practitioners to re-evaluate the methodology. In the present overview, we review the possible contrast-based and contrast agent-free CMR techniques, including native T1 relaxation time, extracellular volume and global longitudinal strain measurement. The review also summarises their potential clinical relevance in CKD patients based on recently published studies.",
keywords = "Cardiac magnetic resonance imaging, Cardiovascular disease, Chronic kidney disease, Myocardial fibrosis",
author = "Eva Kis and Laszlo Ablonczy and G. Reusz",
year = "2018",
month = "3",
day = "1",
doi = "10.1159/000487367",
language = "English",
volume = "43",
pages = "134--142",
journal = "Kidney and Blood Pressure Research",
issn = "1420-4096",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Cardiac Magnetic Resonance Imaging of the Myocardium in Chronic Kidney Disease

AU - Kis, Eva

AU - Ablonczy, Laszlo

AU - Reusz, G.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Early stages of chronic kidney disease (CKD) are often underdiagnosed, while their deleterious effects on the cardiovascular (CV) system are already at work. Thus, the assessment of early CV damage is of crucial importance in preventing major CV events. Myocardial fibrosis is one of the major consequences of progressive CKD, as it may lead to reentry arrhythmias and long-term myocardial dysfunction predisposing to sudden death and/or congestive heart failure. Subclinical myocardial fibrosis, with a potential key role in the development of uraemic cardiac disease, can be measured and characterised by appropriate cardiac magnetic resonance (CMR) techniques. Fibrosis detection was initially based on the contrast agent gadolinium, due to the superiority in sensitivity and accuracy of contrast-based methods in fibrosis assessment relative to native techniques. However, the severe consequences of gadolinium administration in uraemia (nephrogenic systemic fibrosis) have forced practitioners to re-evaluate the methodology. In the present overview, we review the possible contrast-based and contrast agent-free CMR techniques, including native T1 relaxation time, extracellular volume and global longitudinal strain measurement. The review also summarises their potential clinical relevance in CKD patients based on recently published studies.

AB - Early stages of chronic kidney disease (CKD) are often underdiagnosed, while their deleterious effects on the cardiovascular (CV) system are already at work. Thus, the assessment of early CV damage is of crucial importance in preventing major CV events. Myocardial fibrosis is one of the major consequences of progressive CKD, as it may lead to reentry arrhythmias and long-term myocardial dysfunction predisposing to sudden death and/or congestive heart failure. Subclinical myocardial fibrosis, with a potential key role in the development of uraemic cardiac disease, can be measured and characterised by appropriate cardiac magnetic resonance (CMR) techniques. Fibrosis detection was initially based on the contrast agent gadolinium, due to the superiority in sensitivity and accuracy of contrast-based methods in fibrosis assessment relative to native techniques. However, the severe consequences of gadolinium administration in uraemia (nephrogenic systemic fibrosis) have forced practitioners to re-evaluate the methodology. In the present overview, we review the possible contrast-based and contrast agent-free CMR techniques, including native T1 relaxation time, extracellular volume and global longitudinal strain measurement. The review also summarises their potential clinical relevance in CKD patients based on recently published studies.

KW - Cardiac magnetic resonance imaging

KW - Cardiovascular disease

KW - Chronic kidney disease

KW - Myocardial fibrosis

UR - http://www.scopus.com/inward/record.url?scp=85044766463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044766463&partnerID=8YFLogxK

U2 - 10.1159/000487367

DO - 10.1159/000487367

M3 - Article

VL - 43

SP - 134

EP - 142

JO - Kidney and Blood Pressure Research

JF - Kidney and Blood Pressure Research

SN - 1420-4096

IS - 1

ER -